RxDoctor Payments Data

Andrew Boulos, DO

Pulmonary Disease · Colorado Springs, CONPI 1689010100

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,623 of the $14,143 with a category attached, or 68.0%. 41 manufacturers reported payments, led by Pulmonx Corporation at 39.5% of the total.

$14,143in general payments, 2019–2025

Across 409 payments — averaging $34.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pulmonx Corporation$6K
  • Grifols USA, LLC$1K
  • AstraZeneca$1K
  • Sanofi$959
  • Boehringer Ingelheim$693
  • GSK$610
  • plus $4K from 35 others

What the payments were for

  • Consulting fees$3,20023%
  • Travel & lodging$1,1188%
  • Food & beverage$9,62368%
  • Education$2011%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,143 in reported general payments places this provider in the 80th percentile of 248 pulmonary disease providers in Colorado.

See all pulmonary disease providers in Colorado

Medicare billing

Part B allowed, 2024
$139,999
Medicare patients
532
Services billed
1,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate27$389,904
UptraviSelexipag12$262,130
OpsumitMacitentan11$138,078
Trelegy ElliptaFluticasone/Umeclidin/Vilanter98$85,389
Spiriva RespimatTiotropium Bromide82$51,235
Stiolto RespimatTiotropium Br/Olodaterol Hcl46$23,292
EliquisApixaban21$12,082
SymbicortBudesonide/Formoterol Fumarate15$4,610
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$3,584
Albuterol Sulfate HfaAlbuterol Sulfate58$2,346
Roflumilast11$2,155
Ventolin HfaAlbuterol Sulfate32$1,883
Montelukast Sodium97$800
Omeprazole27$487
Prednisone61$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$693$464,431155 claims
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$212$400,20923 claims
GSKTrelegy Ellipta$610$85,38998 claims
PfizerEliquis$128$12,08221 claims
AstraZenecaSymbicort$1,147$4,61015 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 248 pulmonary disease providers in Colorado.

Other pulmonary disease in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →